RESONANT MEDICAL RECEIVES CANADIAN APPROVAL FOR RESTITU

Resonant Medical has received a full Health Canada Medical Device license to market Restitu, its 3D ultrasound image-guided radiotherapy platform, the company said.

Resonant is making its Restitu Platform immediately available to Canadian cancer clinics that wish to use the device to improve the quality of external beam radiation therapy, the firm added. The technology already is being used by roughly 20 percent of all radiation oncology centers in Canada under investigational protocols to perform cutting edge clinical research on prostate cancer as well as head and neck cancer.

The Restitu platform is designed to increase the accuracy and reduce the side-effects of radiation therapy, resulting in improved quality of life for cancer patients as well as enhanced productivity of cancer centers, Resonant said. The proprietary 3D ultrasound technology allows clinicians to target tumors more accurately while safeguarding surrounding healthy tissues, it added.